We used hyperpolarized 13C magnetic resonance spectroscopic imaging (HP 13C MRSI) and T1-MRI to assess dimethyl fumarate (DMF) response in a model of multiple sclerosis (MS). Gadolinium-enhanced T1-MRI showed blood-brain-barrier breakdown, regardless of DMF treatment. In contrast, DMF therapy prevented an increase compared to untreated MS animals in HP 13C lactate, HP 13C lactate-to-pyruvate and HP 13C lactate-to-(pyruvate/urea) ratios. HP 13C MRSI findings were further correlated to pyruvate dehydrogenase activity and pro-inflammatory macrophages. Altogether, we demonstrated that HP 13C MRSI has potential to monitor the effect of immunomodulatory therapies within the central nervous system.
This abstract and the presentation materials are available to members only; a login is required.